Karyopharm Therapeutics, Inc. (KPTI)

NASDAQ: KPTI · Delayed Price · USD
5.71
0.25 (4.58%)
At close: May 17, 2022 4:00 PM
5.69
-0.02 (-0.35%)
After-hours:May 17, 2022 4:53 PM EDT
Market Cap453.48M
Revenue (ttm)234.23M
Net Income (ttm)-108.07M
Shares Out79.42M
EPS (ttm)-1.65
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,673,883
Open5.62
Previous Close5.46
Day's Range5.50 - 5.79
52-Week Range4.42 - 14.73
Beta-0.33
AnalystsBuy
Price Target12.35 (+116.3%)
Earnings DateMay 5, 2022

About KPTI

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with...

IndustryBiotechnology
IPO DateNov 6, 2013
CEOMichael Kauffman
Employees442
Stock ExchangeNASDAQ
Ticker SymbolKPTI
Full Company Profile

Financial Performance

In 2021, KPTI's revenue was $209.82 million, an increase of 94.12% compared to the previous year's $108.09 million. Losses were -$124.09 million, -36.78% less than in 2020.

Financial Statements

Analyst Forecast

According to 16 analysts, the average rating for KPTI stock is "Buy." The 12-month stock price forecast is 12.35, which is an increase of 116.29% from the latest price.

Price Target
$12.35
(116.29% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Antengene Announces XPOVIO® (selinexor) Data to be Presented at the Upcoming 2022 European Hematology Association Hyb...

SHANGHAI and HONG KONG , May 13, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to disc...

4 days ago - PRNewsWire

Karyopharm Announces XPOVIO® (selinexor) Data to be Presented at the European Hematology Association 2022 Hybrid Cong...

NEWTON, Mass. , May 12, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that initial data f...

5 days ago - PRNewsWire

Karyopharm to Participate at the 2022 RBC Capital Markets Global Healthcare Conference

NEWTON, Mass. , May 10, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's ...

1 week ago - PRNewsWire

Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Tops Revenue Estimates

Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of 15.87% and 37.06%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

1 week ago - Zacks Investment Research

Karyopharm Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress

– Achieved First Quarter 2022 Net Revenues of $47.7 Million, Up 105% Versus First Quarter 2021, Including $19.4 Million License Revenues from Partners – – XPOVIO® (selinexor) Net Product Revenue of $28....

1 week ago - PRNewsWire

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEWTON, Mass. , May 2, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that in connection w...

2 weeks ago - PRNewsWire

Karyopharm to Report First Quarter 2022 Financial Results on May 5, 2022

-- Conference Call Scheduled for Thursday, May 5, 2022, at 8:30 a.m. ET -- NEWTON, Mass.

2 weeks ago - PRNewsWire

Karyopharm Announces Selinexor Data to be Presented at the 2022 American Society of Clinical Oncology Annual Meeting

NEWTON, Mass. , April 27, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that four abstract...

2 weeks ago - PRNewsWire

Karyopharm Therapeutics (KPTI) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Karyopharm Therapeutics (KPTI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 weeks ago - Zacks Investment Research

Karyopharm to Participate at the Canaccord Genuity Horizons in Oncology Conference

NEWTON, Mass. , April 7, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's...

1 month ago - PRNewsWire

Karyopharm Announces Further Transition of Co-Founders Sharon Shacham PhD, MBA and Michael Kauffman, MD, PhD and appo...

- Formerly of Aravive, Genmab and Merck & Co., Dr. Rangwala will Lead Karyopharm's Clinical Development Programs and Strategy - - As Part of Karyopharm's Evolution, Co-Founders Dr. Shacham and Dr. Kauff...

1 month ago - PRNewsWire

Karyopharm Announces Upcoming Presentations of Phase 3 SIENDO Study of Selinexor in Patients with Advanced or Recurre...

Study Results to be Presented at the European Society of Medical Oncology's  Virtual Plenary and the Society for Gynecologic Oncology 2022 Annual Meeting on Women's Cancer Company to Host Investor Confe...

2 months ago - PRNewsWire

Karyopharm Names New Head of Investor Relations

– Elhan Webb, CFA, Formerly of Rubius Therapeutics and Radius Health, Appointed as Senior Vice President of Investor Relations – – Webb Brings More than 20 Years of Diverse International Experience Acro...

2 months ago - PRNewsWire

Karyopharm to Participate at the Barclays Global Healthcare Conference

NEWTON, Mass. , March 9, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's...

2 months ago - PRNewsWire

Why Are Karyopharm Shares Trading Lower Today

Karyopharm Therapeutics Inc (NASDAQ: KPTI) stock plunged after an update on its supplemental New Drug Application submission based on the Phase 3 SIENDO study data of selinexor as front-line maintenance...

2 months ago - Benzinga

Karyopharm Provides U.S. Regulatory Update on Selinexor in Advanced or Recurrent Endometrial Cancer

NEWTON, Mass., March 1, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today provided an update on its disc...

2 months ago - PRNewsWire

Here's Why Karyopharm Therapeutics Is Sliding on Tuesday

Investors aren't pleased with the surprise departure of the company's chief medical officer.

2 months ago - The Motley Fool

Why Are Karyopharm Shares Plunging Today?

Karyopharm Therapeutics Inc (NASDAQ: KPTI) revealed that executive vice president and chief medical officer Jatin Shah departs for "other professional opportunities." While CEO Paulson looks for Shah's ...

2 months ago - Benzinga

Karyopharm Announces Changes to Its Clinical Leadership Team

NEWTON, Mass., Feb. 22, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced changes to its clini...

2 months ago - PRNewsWire

Karyopharm to Participate at 11th Annual SVB Leerink Global Healthcare Conference

NEWTON, Mass., Feb. 11, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Richard Paulso...

3 months ago - PRNewsWire

Why Karyopharm Therapeutics Stock Was a Winner on Wednesday

An analyst upgrade that followed much better-than-expected quarterly results put some real zip into the biotech's stock.

3 months ago - The Motley Fool

Why Karyopharm Therapeutics Stock Is Falling Today

Fourth-quarter sales of Xpovio were encouraging, but top-line results from another trial were a little disappointing.

3 months ago - The Motley Fool

Karyopharm Therapeutics (KPTI) Tops Q4 Earnings and Revenue Estimates

Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of 215% and 125.56%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Karyopharm Reports Strong Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company Progress

NEWTON, Mass., Feb. 8, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI) ("Karyopharm," the "Company," "we" and "our"), a commercial-stage pharmaceutical company pioneering novel cancer t...

3 months ago - PRNewsWire

Karyopharm Announces Phase 3 SIENDO Study Meets Primary Endpoint with Statistically Significant Increase in Progressi...

NEWTON, Mass., Feb. 8, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced positive top-line re...

3 months ago - PRNewsWire